Bibliography
Found 48 results
Filters: Author is Letendre, Scott and Keyword is Adult [Clear All Filters]
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013 ;8(5):1123-35.
. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology. 2013 ;80(15):1415-23.
. Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011 ;33(5):505-22.
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010 ;54(12):5156-60.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.
Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. Journal of Neurovirology [Internet]. 2007 ;13:150-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17505983
. Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists [Internet]. 2007 ;22:187-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17289343
. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. The Journal of Infectious Diseases [Internet]. 2007 ;196:361-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17597450
Lithium improves HIV-associated neurocognitive impairment. AIDS (London, England) [Internet]. 2006 ;20:1885-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16954730
. Markers of macrophage activation and axonal injury are associated with prospective memory in HIV-1 disease. Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology [Internet]. 2006 ;19:217-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17159619
. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology [Internet]. 2006 ;12:100-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16798671
. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology [Internet]. 2006 ;179:180-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16901548
.